Background: Effective adjuvant or neoadjuvant regimens of chemotherapy have dramatically
improved the prognosis of patients with high-grade osteosarcoma of the extremity, localized …

Background Most of the studies of the treatment of non-metastatic osteosarcoma of the
extremity have reported results in terms of probability of survival up to five years with a …

Abstract Between September 1986 and December 1988, 125 patients with osteosarcoma of
the extremities entered the second neoadjuvant study at the authors' institution. Patients …

BACKGROUND Risk factors for local recurrence (LR) after osteosarcoma, such as surgical
margins and histologic response to preoperative treatment, have been well documented …

Background To identify predictive factors of disease-free survival (DFS) in patients with non-
metastatic osteosarcoma of the extremity, treated with primary chemotherapy and delayed …

BACKGROUND The evaluation variables influencing systemic and local recurrence and
final outcome are extremely important in defining risk‐adapted treatments for patients with …

From January 1993 to March 1995, 162 patients with osteosarcoma of extremities were
treated according to the IOR/OS-4 protocol. 133 patients had localised disease, while 29 …

Around 1148 patients with non-metastatic osteosarcoma of the extremity were treated in a
single institution between 1972 and 1999 with 4 different protocol of adjuvant and 7 different …

PURPOSE: To provide an estimate of long-term prognosis for patients with osteosarcoma of
the extremity treated in a single institution with neoadjuvant chemotherapy and observed for …

Purpose We compared two chemotherapy regimens that included methotrexate (MTX),
cisplatin (CDP), and doxorubicin (ADM) with or without ifosfamide (IFO) in patients with …